Schedule 13G ownership disclosure

Apellis Pharmaceuticals Inc

Security class unavailable · CUSIP: 03753U106

Event date: 2023-12-31

Legacy cover-page extraction is best effort and may not include every reporting person.

Filing-level shares
11,173,068
Percent of class
9.4000%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000935836-24-000205
Form type
SC 13G/A
Filer
Apellis Pharmaceuticals, Inc.
CIK
CIK 1492422
Filed
Feb 14, 2024
Reporting period
Dec 31, 2023
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub